Search
Pediatric NM Disorders
Browse:
  • Featured
  • Catalog
Sort By
Image For Activity Cover
On-Demand
 1 CME  1 CEU
$0.00 - $25.00
Image For Activity Cover
Bundle
 100 CME  100 CEU
$295.00 - $445.00
Image For Activity Cover
On-Demand
 3 CEU  1 Checkpoint
$15.00 - $35.00
Image For Activity Cover
On-Demand
 0.25 CME  0.25 CEU
Free
Image For Activity Cover
On-Demand
 1 CME  1 CEU
$0.00 - $25.00
Image For Activity Cover
On-Demand
 2 CME  2 CEU
$0.00 - $15.00
Image For Activity Cover
On-Demand
 1 CME  1 CEU
$0.00 - $25.00
Image For Activity Cover
Bundle
 86.5 CME  86.5 CEU
$295.00
Image For Activity Cover
On-Demand
 1 CME
$0.00 - $25.00
Image For Activity Cover
On-Demand
 1 CME  1 CEU
$0.00 - $25.00
Image For Activity Cover
Bundle
 86.5 CME  36 SA CME  86.5 CEU
$295.00
Image For Activity Cover
On-Demand
 2 CME  2 CEU
$0.00 - $15.00
Image For Activity Cover

7/23/2021- Dr. Priya Dhawan interviews Drs. Mohamed Kazamel & Robert Desnick on their article, Porphyric Neuropathy Part II.   35 minutes
On-Demand
 No Credit
Free
Image For Activity Cover
On-Demand
 3 CME  3 CEU
Free
Image For Activity Cover
Technologist Copes with Interfering and Condescending Parent of Child Patient
On-Demand
 1 CME  1 CEU
$0.00 - $25.00
Image For Activity Cover

12/19/2013-  Spinal muscular atrophy: development and implementation of potential treatments by Drs. David Arnold and Arthur Burghes. Ann Neurol. 2013 Sep;74(3):348-62. doi: 10.1002/ana.23995. This podcast is a brief discussion of the article in Annals in Neurology. The article discusses the rapid progress in the understanding of recessive proximal spinal muscular atrophy and how this is leading to exciting potential treatments of the disease. Spinal muscular atrophy is caused by loss of the survival motor neuron 1 (SMN1) gene and reduced levels of SMN protein. The critical downstream targets of SMN deficiency that result in motor neuron loss are not known. However, increasing SMN levels has a marked impact in mouse models, and these therapeutics are rapidly moving toward clinical trials. Promising preclinical therapies, the varying degree of impact on the mouse models, and potential measures of treatment effect are reviewed. One key issue discussed is the variable outcome of increasing SMN at different stages of disease progression.
On-Demand
 No Credit
Free
Image For Activity Cover

3/10/2011-  An interview with Drs. Robert Leshner and Paula Clemens about the article A randomized study of alglucosidase alfa in late-onset Pompe's disease in N Engl J Med. 2010 Apr 15;362(15):1396-406.
On-Demand
 No Credit
Free
Image For Activity Cover

8/5/2010- An interview with Dr. Krista Kuitwaard about Pharmacokinetics of IVIg and outcome in GBS. Annals Neurol 2009;66:597-603.
On-Demand
 No Credit
Free
Image For Activity Cover

7/21/2009-  An interview with Joshua Burns, PhD, about the paper, Ascorbic acid for Charcot–Marie–Tooth disease type 1A in children: a randomized, double-blind, placebo-controlled, safety and efficacy trial in Lancet Neurol. 2009 Jun;8(6):537-44. Interviewed by Ted Burns, MD.
On-Demand
 No Credit
Free
Image For Activity Cover

11/4/2008 -  An interview with H. Royden Jones, MD about Pediatric Electromyography. Interviewed by Edward Smith, MD and John Mytinger, MD.
On-Demand
 No Credit
Free
Course 1 to 20 of 21


2621 Superior Drive NW
Rochester, MN

P 507.288.0100

F 507.288.1225

aanem@aanem.org

Terms of Use
Privacy Statement
                   

© 2024 American Association of Neuromuscular & Electrodiagnostic Medicine
Powered By